JP2025060686A5 - - Google Patents

Info

Publication number
JP2025060686A5
JP2025060686A5 JP2024218275A JP2024218275A JP2025060686A5 JP 2025060686 A5 JP2025060686 A5 JP 2025060686A5 JP 2024218275 A JP2024218275 A JP 2024218275A JP 2024218275 A JP2024218275 A JP 2024218275A JP 2025060686 A5 JP2025060686 A5 JP 2025060686A5
Authority
JP
Japan
Prior art keywords
composition
atrasentan
human subject
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024218275A
Other languages
English (en)
Japanese (ja)
Other versions
JP7821870B2 (ja
JP2025060686A (ja
Filing date
Publication date
Priority claimed from JP2022537007A external-priority patent/JP7624995B2/ja
Application filed filed Critical
Publication of JP2025060686A publication Critical patent/JP2025060686A/ja
Publication of JP2025060686A5 publication Critical patent/JP2025060686A5/ja
Application granted granted Critical
Publication of JP7821870B2 publication Critical patent/JP7821870B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024218275A 2019-12-17 2024-12-12 アトラセンタンによるｉｇａ腎症を治療する方法 Active JP7821870B2 (ja)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US201962949115P 2019-12-17 2019-12-17
US62/949,115 2019-12-17
US202063005003P 2020-04-03 2020-04-03
US63/005,003 2020-04-03
US202063072699P 2020-08-31 2020-08-31
US63/072,699 2020-08-31
US202063084739P 2020-09-29 2020-09-29
US63/084,739 2020-09-29
US202063125205P 2020-12-14 2020-12-14
US63/125,205 2020-12-14
JP2022537007A JP7624995B2 (ja) 2019-12-17 2020-12-16 アトラセンタンによるｉｇａ腎症を治療する方法
PCT/US2020/065311 WO2021126977A1 (en) 2019-12-17 2020-12-16 Methods of treating iga nephropathy with atrasentan

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022537007A Division JP7624995B2 (ja) 2019-12-17 2020-12-16 アトラセンタンによるｉｇａ腎症を治療する方法

Publications (3)

Publication Number Publication Date
JP2025060686A JP2025060686A (ja) 2025-04-10
JP2025060686A5 true JP2025060686A5 (https=) 2025-10-27
JP7821870B2 JP7821870B2 (ja) 2026-02-27

Family

ID=76478538

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022537007A Active JP7624995B2 (ja) 2019-12-17 2020-12-16 アトラセンタンによるｉｇａ腎症を治療する方法
JP2024218275A Active JP7821870B2 (ja) 2019-12-17 2024-12-12 アトラセンタンによるｉｇａ腎症を治療する方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022537007A Active JP7624995B2 (ja) 2019-12-17 2020-12-16 アトラセンタンによるｉｇａ腎症を治療する方法

Country Status (21)

Country Link
US (11) US20210353593A1 (https=)
EP (2) EP4076652B1 (https=)
JP (2) JP7624995B2 (https=)
KR (1) KR20230015874A (https=)
CN (3) CN116173014A (https=)
AU (1) AU2020404984A1 (https=)
BR (1) BR112022012075A2 (https=)
CA (1) CA3161516A1 (https=)
DK (1) DK4076652T3 (https=)
FI (1) FI4076652T3 (https=)
HR (1) HRP20260121T1 (https=)
IL (1) IL293921A (https=)
LT (1) LT4076652T (https=)
MX (1) MX2022007471A (https=)
PH (1) PH12022551456A1 (https=)
PL (1) PL4076652T3 (https=)
PT (1) PT4076652T (https=)
RS (1) RS67746B1 (https=)
SI (1) SI4076652T1 (https=)
TW (1) TWI875895B (https=)
WO (1) WO2021126977A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3161516A1 (en) 2019-12-17 2021-06-24 Philip Thomas FROHLICH Methods of treating iga nephropathy with atrasentan
CN114910647A (zh) * 2022-05-07 2022-08-16 浙江大学 细丝蛋白-A-IgG抗体在制备检测血管内皮损伤试剂盒中的应用
WO2023220930A1 (en) * 2022-05-17 2023-11-23 Increvet, Inc. Veterinary pharmaceutical formulations cross-references to related applications
CN119325377A (zh) * 2022-05-19 2025-01-17 奇努克治疗公司 用阿曲生坦治疗局灶节段性肾小球硬化的方法
WO2024073672A1 (en) 2022-09-30 2024-04-04 Travere Therapeutics, Inc. Combination therapy with sparsentan and a sglt2 inhibitor for treating kidney diseases or disorders
WO2024076177A1 (ko) * 2022-10-05 2024-04-11 주식회사 대웅제약 이나보글리플로진을 포함하는 신장애 및/또는 당뇨병 예방 또는 치료용 약학 조성물
AU2023366516A1 (en) * 2022-10-28 2025-05-15 Aduro Biotech Holdings, Europe B.V. Treatment of iga nephropathy using an endothelin receptor antagonist and an april binding antibody
JP2025536433A (ja) 2022-11-07 2025-11-05 サンレノ セラピューティクス （シャンハイ） リミテッド ＩｇＡ腎症を治療するためのエンドセリン受容体アンタゴニストとグルココルチコイドとの組み合わせ
WO2025261457A1 (zh) * 2024-06-21 2025-12-26 深圳信立泰药业股份有限公司 内皮素a(eta)受体拮抗剂联用sglt-2抑制剂的医药用途

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5236940A (en) 1988-12-15 1993-08-17 Rhone-Poulenc Sante Pharmaceutical compositions, 2-benzothiazolamine derivatives, and their preparation
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
US7365093B2 (en) 1994-08-19 2008-04-29 Abbott Laboratories Endothelin antagonists
US7208517B1 (en) 1994-08-19 2007-04-24 Abbott Labortories Endothelin antagonists
US6946481B1 (en) 1994-08-19 2005-09-20 Abbott Laboratories Endothelin antagonists
US20020062121A1 (en) 1995-05-16 2002-05-23 Karl Tryggvason Perfusion apparatus and methods for pharmaceutical delivery
PT885215E (pt) 1996-02-13 2006-08-31 Abbott Lab Novos derivados de pirrolidina substituidos com benzo-1,3-dioxolilo e benzofuranilo como antagonistas de endotelina
US20040191774A1 (en) 2001-09-11 2004-09-30 Moskowitz David W Endothelin-1 promoter polymorphism
KR100964908B1 (ko) 2002-03-22 2010-06-23 깃세이 야쿠힌 고교 가부시키가이샤 신장질환의 예방 또는 치료제
AU2003226356A1 (en) 2002-04-12 2003-10-27 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
US20030229906A1 (en) 2002-04-15 2003-12-11 Gelman Irwin H. Methods and compositions for the treatment of disorders of HIV infection
US9388427B2 (en) 2002-12-02 2016-07-12 Biovec, Llc In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors
US7410483B2 (en) 2003-05-23 2008-08-12 Novare Surgical Systems, Inc. Hand-actuated device for remote manipulation of a grasping tool
US20110142858A1 (en) 2004-06-07 2011-06-16 Ramot At Tel Aviv University Ltd. Method of Passsive Immunization Against Disease or Disorder Charcterized by Amyloid Aggregation with Diminished Risk of Neuroinflammation
EP1802610A1 (en) 2004-09-17 2007-07-04 Abbott Laboratories Crystalline form 2 of atrasentan hydrochloride
US9051301B2 (en) 2004-09-17 2015-06-09 Abbvie Inc. Crystalline form of a drug
US20060135596A1 (en) 2004-09-17 2006-06-22 Zhang Geoff G Amorphous form of a drug
WO2006034094A1 (en) 2004-09-17 2006-03-30 Abbott Laboratories Crystalline form 1 of atrasentan hxdrochloride
EP2012751A4 (en) 2006-03-21 2010-11-24 Morehouse School Of Medicine NEW NANOPARTICLES FOR THE ACTIVE COMPOSITION
BRPI0709411A2 (pt) * 2006-03-27 2011-07-12 Genentech Inc método para tratamento de uma doença renal
SG174050A1 (en) 2006-04-13 2011-09-29 Actelion Pharmaceuticals Ltd Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
CA2667364A1 (en) 2007-01-16 2008-07-24 Musc Foundation For Research Development Compositions and methods for diagnosing, treating, and preventing prostate conditions
CA2695259C (en) 2007-07-31 2016-05-24 Gilead Colorado, Inc. Metabolites and derivatives of ambrisentan
EP2545920A1 (en) 2007-08-22 2013-01-16 Abbott GmbH & Co. KG Therapy for complications of diabetes
US20120083421A1 (en) 2008-10-16 2012-04-05 The Trustees Of Columbia University In The City Of New York Use of urinary ngal to diagnose and monitor hiv-associated nephropathy (hivan)
WO2010114801A1 (en) 2009-03-31 2010-10-07 Ligand Pharmaceuticals Inc. Oral formulations of diphenylsulfonamide endothelin and angiotensin ii receptor agonists to treat elevated blood pressure and diabetic nephropathy
EP2509594A1 (en) 2009-12-09 2012-10-17 INSERM - Institut National de la Santé et de la Recherche Médicale Endothelin inhibitors for the treatment of rapidly progressive glomerulonephritis
US9255931B2 (en) * 2010-06-24 2016-02-09 Morehouse School Of Medicine Method and compositions for the treatment and detection of endothelin-1 related kidney diseases
CN103025670B (zh) 2010-07-28 2016-08-10 日本电气硝子株式会社 荧光体封入用毛细管的制造方法、荧光体封入用毛细管、波长变换部件和波长变换部件的制造方法
CN105324395A (zh) * 2013-03-08 2016-02-10 艾伯维公司 治疗急性肾损伤的方法
KR20160003128A (ko) 2013-04-30 2016-01-08 애브비 인코포레이티드 아트라센탄을 사용하는 지질 프로파일을 개선시키기 위한 방법
US9364458B2 (en) * 2013-07-08 2016-06-14 Abbvie Inc. Stabilized pharmaceutical dosage forms comprising atrasentan
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
US8962675B1 (en) 2013-09-12 2015-02-24 Abbvie Inc. Atrasentan mandelate salts
AU2015342929A1 (en) * 2014-11-07 2017-05-25 Abbvie Inc. Methods of treating CKD using predictors of fluid retention
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
US20170014386A1 (en) 2015-07-16 2017-01-19 Abbvie, Inc. Treatment of Multidrug-Resistant Nephrotic Syndrome (MDR-NS) in Children
IL300122A (en) * 2015-11-18 2023-03-01 Merck Sharp ַ& Dohme Llc Substances that bind to PD1 and/or LAG3
KR102528260B1 (ko) 2016-01-05 2023-05-04 유니버시티 오브 레스터 필요로 하는 대상체에서 섬유증의 억제 방법
CN117017985A (zh) * 2016-10-13 2023-11-10 特拉维尔治疗公司 用于治疗肾脏疾病或病症的联苯磺酰胺化合物
RU2765737C2 (ru) 2016-11-23 2022-02-02 Хемоцентрикс, Инк. Способ лечения фокально-сегментарного гломерулосклероза
RU2020113612A (ru) 2017-10-11 2021-11-12 Хемоцентрикс, Инк. Лечение фокально-сегментарного гломерулосклероза антагонистами ccr2
CN111405899B (zh) 2017-11-30 2025-05-16 爱杜西亚药品有限公司 用于治疗内皮素相关疾病的4-嘧啶磺酰胺衍生物与sglt-2抑制剂的组合
US20220304979A1 (en) 2019-12-17 2022-09-29 Chinook Therapeutics, Inc. Methods of reducing disease flares
CA3161516A1 (en) * 2019-12-17 2021-06-24 Philip Thomas FROHLICH Methods of treating iga nephropathy with atrasentan
IL297208A (en) 2020-04-10 2022-12-01 Chinook Therapeutics Inc Treatment methods for diabetic kidney disease
US20220243994A1 (en) 2021-02-04 2022-08-04 Northrop Grumman Systems Corporation Metal woodpile capillary wick

Similar Documents

Publication Publication Date Title
JP2025060686A5 (https=)
EP4512397A2 (en) New use of a combination of an angiotensin receptor blocker (arb) with a neutral endopeptidase inhibitor (nepi)
US10206919B2 (en) Use of levocetirizine and montelukast in the treatment of vasculitis
JP2024127897A5 (https=)
TWI406858B (zh) 炎症性腸道疾病治療藥
US20150320721A1 (en) Combinations of sglt 2 inhibitors and antihypertensive drugs
Dominguez Rieg et al. New functions and roles of the Na+-H+-exchanger NHE3
Fenier et al. Enalapril improved renal function and proteinuria in chronic glomerulopathies
EP2837380B1 (en) Lercanidipine hydrochloride and losartan potassium compound preparation and preparation method thereof
JP7668386B2 (ja) １－（３－シアノ－１－イソプロピル－インドール－５－イル）ピラゾール－４－カルボン酸を含む薬学的組成物
US20110130421A1 (en) Methods and Compositions for the Treatment of Chronic Renal Hypertension
Sahai et al. Pharmacology of the Therapeutic Approaches of Gout
KR20230119303A (ko) 높은 혈중 요산 농도를 갖는 대상체의 만성 신장 질환의 예방 또는 치료를 위한 알로푸리놀, 페북소스타트 또는 이들의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물
EP2586442A1 (en) Sustained-release therapeutic agent for hypertension and renal dysfunction
EP4043018A1 (en) Composition and method for reducing oxalate levels in patients receiving maintenance dialysis
RU2741426C1 (ru) Никотинамид для лечения дислипидемии
US20150119401A1 (en) Compositions and Methods for the Treatment of Nasal Conditions
CN101014333A (zh) 包含洛索洛芬的口服组合物
Varda et al. Diabetic Kidney Disease: From Pathophysiology To Treatment Perspectives
TWI907583B (zh) Jak抑制劑在腎臟疾病中的應用
WO2022225044A1 (ja) カリウム吸着薬を有効成分とする慢性腎不全（ｃｋｄ）合併高カリウム血症患者の予後改善剤
Groothoff et al. Long-Term Nedosiran Safety and Efficacy in Primary Hyperoxaluria Type 1 (PH1): Interim Analysis of PHYOX3: TH-PO1128
CN117241795A (zh) 治疗脓毒症的硝唑尼特
US8952011B2 (en) Compositions and methods for the treatment of nasal conditions
JP2025527620A (ja) チロシンキナーゼ阻害剤ボドバチニブを使用した慢性骨髄性白血病を治療する方法